Introduction
Abundant anatomical and physiological evidence has suggested a role for the central and autonomic nervous systems in the regulation of hepatic function (1) (2) (3) .
Neuropeptides have been recognized as neurotransmitters in the central and peripheral nervous systems (4-6), and centrally acting neuropeptides have been reported to regulate a variety of physiological functions including of digestive system (7-9) through autonomic nervous systems. We have paid attention to the relationshp between central nervous system and hepatobiliary system, and in previous study we have shown that central TRH enhances hepatic blood flow (10) and hepatic proliferation (11), and also central Neuropeptide Y increases bile secretion through the parasympathetic nervous systems (12, 13) . In the pathophygiological function of the liver, we have revealed that central TRH protects CCl4-induced acute liver injury through vagal-cholinergic patheway (14), but central CRF exacerbates the experimental acute liver injury through the sympathetic-noradrenergic pathways in rats (15).
Corticotropin-releasing factor (CRF) is one of the central neuropeptides, and effect of central CRF on physiological, pharmacological, and pathophysiological regulations of the digestive system have been reported (15) (16) (17) (18) (19) (20) (21) (22) . Recently two G protein-coupled receptors have been identified that bind CRF and its agonist family (urocortin, savagin, urotensin I), and named CRF1 receptor and CRF2-receptor (23) (24) (25) (26) (27) (28) .
Urocortin is a recently isolated 40 amino acid-containing neuropepetide and shares 45 % sequence homology with CRF (29) . While urocortin and CRF both display a similar high affinity for the CRF1 receptor, the affinity of urocortin for the CRF2-receptor is more than 10-fold higher than that of CRF (30) .
In this study, we investigate that the effect of urocortin on the CCl4-induced acute liver injury in rats and the involvement of CRF receptors in the exacerbating effect of the experimental liver injury.
Material and Methods

Animals
Male Wistar rats weighing 280-320 g (Charles River Japan Inc., Yokohama, Japan) were housed in group cages under condition of controlled temperature (22) (23) (24) oC) and illumination (12-h light cycle starting at 6 AM) for at least 7 days before experiments. Animals were maintained on laboratory chow and water. Experiments were performed in rats deprived of foods for 12 h (starting at 6 PM), but given free access to water up to the beginning of the study. Protocols describing the use of rats were approved by the Animal Care Committee of Asahikawa Medical College, and in accordance with the National Institute of Health "Guide for the Care and Use of Laboratory Animals".
Drugs
The following substances were used: rat urocortin (Peptide Institute Inc., Osaka, Japan), carbon tetrachloride (CCl4, Wako Pure Chemical Industries, Osaka, Japan), Phenol (Wako). Urocortin was dissolved in 0.9 % saline (pH 7.4) before the experiment and injected intracisternally in 10 µl using a 50-µl Hamilton microsyringe (Hamilton Co., Reno, NV).
Experimental design
After 12 h fasting, rats were anesthetized with ether and mounted on ear bars proximal to the cardia under a dissection microscope (31) . To exclude the effect of denervation of hepatic plexus, and hepatic branch vagotomy on food intake, rats were pair-fed with respective vehicle treated-or sham operated-rats.
Statistical Analysis
All results were expressed as mean ± SE. Comparison between two independent groups was calculated by unpaired Student's t test. Multiple group comparisons were performed by analysis of variance (ANOVA) followed by Fisher's LSD. A P value < 0.05 was considered statistically significant.
Results
Effect of intracisternal urocortin on CCl4-induced acute liver injury
Histological studies revealed dose-dependent aggravating effect of intracisternal urocortin injection on CCl4-induced hepatic degeneration and necrosis area surrounded by foamy cells (Mean ± SE, %: saline 5.5 ± 1.2; 0.5 µg 6.3 ± 3.0; 1 µg 10.5 ± 2.2; 3 µg 17.5 ± 2.0; 5 µg 28.1 ± 4.0; 10 µg 23.5 ± 2.3; n=5-6) ( Fig. 1, 2) . Also intracisternal injection of urocortin (just before and 6 h after CCl4 injection) dose-dependently enhanced the CCl4-induced elevation of serum AST (Mean ± SE, IU/L: saline 110 ± 14; 0.5 µg 138 ± 32; 1 µg 166 ± 21; 3 µg 407 ± 111; 5 µg 866 ± 464; 10 µg 592 ± 245; n=5-6) and ALT levels (Mean ± SE, IU/L: saline 19 ± 2; 0.5 µg 20 ± 8; 1 µg 25 ± 3; 3 µg 44 ± 9; 5 µg 81 ± 25; 10 µg 79 ± 30; n=5-6) (Fig. 2) .
Intravenously administration of CRF (10 µg) did not influence the CCl4-induced heparic regeneration and necrosis area, and elevation of serum transaminase level ( Table 1) .
Effect of hepatic plexus denervation and hepatic branch vagotomy on intracisternal urocortin-induced enhancement of acute liver injury by CCl4.
Denervation of hepatic plexus by 85% phenol (7 days before) completely abolished the aggravating effect of intracisternal urocortin (5 µg) on the CCl4-induced hepatic degenertion and necrosis, and elevation of serum transaminase level and (Fig.3) .
On the other hand, hepatic branch vagotomy (3 days before) did not influence the aggravating effect of intracisternal injection of urocortin (5 µg) on the CCl4-induced hepatic degeneration and necrosis, and elevation of serum transaminase level (Fig. 3) .
Discussion
In the present study, we demonstrated that intracisternal injection of urocortin exacerbated CCl4-induced acute liver injury in rats. We measured serum AST and ALT levels, and also examined histological changes of the liver. Intracisternal urocortin dose-dependently enlarged the CCl4-induced hepatic degeneration and necrosis.
Similary intracisternal urocortin dose-dependently enhanced the CCl4-induced elevation of serum AST and ALT levels. The increase of serum transaminase levels and hepatic regeneration and necrosis areas by intracisternal injection of urocortin was dose-related in doses ranging from 0.5 to 5 µg. Administration of up to 10 µg of urocortin did not further enhance the CCl4-induced increase of serum transaminase levels and hepatic regeneration and necrosis areas, indicating that maximal effect were achieved with 5 µg dose. In contrast, urocoritn injected intravenously at the maximal effective intracisternal dose did not influence CCl4-induced acute liver injury. These results indicate that urocortin injected into the cisternal magna, acts in the central nervous system to aggravate CCl4-induced acute liver injury and not through leakage into the peripheral circulation (32).
The pathways through which central administration of urocortin enhanced CCl4-induced acute liver injury were investigated. In the present study, the enhancement of CCl4-induced acute liver injury by intracisternal injection of urocortin was completely abolished by denervation of hepatic plexus by 85% phenol, whereas hepatic branch vagotomy had no effect. Since the treatment of hepatic plexus with phenol is known to dominantly denervate the hepatic sympathetic nerve (1), these results indicate that urocortin acts centrally to enhance CCl4-induced acute liver injury in rats through sympathetic nervous system similar to the central CRF.
CRF is one of the central neuropeptides, and it affects peripheral organ through the autonomic nervous system (21) . In regard to the digestive system previous reports have shown that central CRF inhibits gastric secretion and motility and exocrine secretion of the pancreas through sympathetic-noradrenergic nervous system (16, 17, 20, 22) . Meanwhile, central CRF stimulates the colonic motility through parasympathetic nervous system (18, 19) . And also we have reported central CRF exacerbated CCl4-induced acute liver injury in rats through sympathetic-noradrenergic nervous system (15).
Recently, two G protein-coupled receptors have been identified that bind CRF and its agonist family (urocortin, savagin, urotensin I) (23) (24) (25) (26) (27) (28) . they are named CRF1 receptor and CRF2-receptor, and have identified their role or distribution in central nervous system and peripheral organs (33) . In regard to digestive system, it is reported that the different subtype of CRF receptors mediate motility of gastrointestinal tract (34, 35) .
Urocortin is a recently isolated 40 amino acid-containing neuropepetide and shares 45 % sequence homology with CRF (29) . While urocortin and CRF both display a similar high affinity for the CRF1 receptor, the affinity of urocortin for the CRF2-receptor is more than 10-fold higher than that of CRF (29, In conclusion, the present data indicate that urocortin injected intracisternally acts in the brain to induce a potent enhancement of CCl4-induced acute liver injury in rats. The peptide action is mediated through a sympathetic pathways. Central injection of urocortin provides a useful tool to further investigate brain sites that influence sympathetic regulation of liver injury. The effect of intracisternal urocortin on CCl4-induced hepatic histological changes. Saline (A) or urocortin (5 µg) (B) was injected intracisternally just before and 6 h after CCl4 (2ml/kg) administtrasion, and the liver tissues were obtained 24 h after CCl4 administration and the specimens were stained with Hematoxylin & Eosin (75 x).
Fig. 2
The dose response of intracisternal urocortin effect on CCl4-induced hepatic histological change and elevation of serum transaminase levels. Saline or urocortin (0.5, 1, 3, 5 or 10 µg) was injected intracisternally and 6 h after CCl4 (2 ml/kg) administration. Control animals were intracisternally injected with saline just before and 6 h after CCl4 administration. Liver tissues and blood samples were collected 24 h after CCl4 administration.Each column represents the mean ± SE of hepatic necrosis and regeneration areas and serum transaminase levels. *P < 0.05, **P < 0.01 compared with saline injection group. Fig. 3 The effect of hepatic plexus denervation and hepatic branch vagotomy on the intracisternal urocotin-induced enhancement of the hepatic histological change and elevation of serum ALT levels by CCl4. Hepatic plexus denervation by 85% phenol was performed 7 days before and hepatic branch vagotomy was performed 3 days before CCl4 administration. Saline or urocortin (5 µg) was injected intracisternally just before and 6 h after CCl4 (2ml/kg) administration. Each column represents the mean ± SE. *P < 0.05, **P < 0.01 compared with respective control group.
